Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of ...
Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.
One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali plus endocrine therapy, according to MONALEESA data presented at SABCS 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback